Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Uwe Bamberger

Armin Heckel

Jose William Saldanha

Wolfgang J Rettig

John Edward Park

Annerose Mauz

Pilar Garin-Chesa

Olivier L&egrave;ger

Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.

FAP&agr;-specific antibody with improved producibility

The invention relates to trisubstituted pyrimido [5,4-d]-pyrimidines of general formula ##STR1## (wherein R.sub.a, R.sub.b and R.sub.c are defined as in claim 1) and the salts thereof, more particularly for pharmaceutical use the physiologically acceptable salts thereof, which have, inter alia, valuable pharmacological properties, particularly in chemotherapy a sensitizing effect on resistant tumors, the use thereof and processes for preparing them.

Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug

Growing community of inventors

Ochsenhausen, Germany

Uwe Bamberger